R&D Spending Showdown: Madrigal Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.

Pharma R&D: Madrigal vs. Celldex - A Decade of Innovation

__timestampCelldex Therapeutics, Inc.Madrigal Pharmaceuticals, Inc.
Wednesday, January 1, 201410438100068205000
Thursday, January 1, 201510017100054218000
Friday, January 1, 201610272600015934000
Sunday, January 1, 20179617100024390000
Monday, January 1, 20186644900025389000
Tuesday, January 1, 20194267200072324000
Wednesday, January 1, 202042534000184809000
Friday, January 1, 202153311000205164000
Saturday, January 1, 202282258000245441000
Sunday, January 1, 2023118011000271823000
Loading chart...

In pursuit of knowledge

R&D Spending Trends: A Decade of Innovation

In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Madrigal Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. have been at the forefront of this race.

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals has shown a remarkable increase in R&D spending, with a staggering 300% rise from 2014 to 2023. This surge underscores their dedication to pioneering new treatments and therapies. By 2023, their R&D expenses reached a peak, reflecting their strategic focus on long-term growth and innovation.

Celldex Therapeutics, Inc.

Celldex Therapeutics, on the other hand, experienced a more fluctuating trend. While their R&D spending decreased by about 60% from 2014 to 2019, they rebounded with a 177% increase by 2023. This recovery highlights their resilience and adaptability in a rapidly evolving industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025